Response to Editor: Commentary on "Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma"

被引：0
|
作者：
Chen, Qin [1 ,2 ,3 ]
Wang, Xinyue [1 ,2 ]
Jiang, Richeng [1 ,2 ,4 ,5 ]
机构：
[1] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Tianjin Lung Canc Ctr, Dept Thorac Oncol, Tianjin, Peoples R China
[2] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[3] Tianjin Chest Hosp, Dept Resp & Crit Med, Tianjin, Peoples R China
[4] Tianjin Canc Hosp, Airport Hosp, Canc Precise Diag Ctr, Tianjin, Peoples R China
[5] Tianjin Med Univ Canc Inst & Hosp, Ctr Precis Canc Med & Translat Res, Tianjin, Peoples R China
来源：
CLINICAL LUNG CANCER | 2024年 / 25卷 / 08期
基金：
中国国家自然科学基金;
关键词：
THERAPY; MECHANISM;
D O I：
10.1016/j.clc.2024.08.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e479 / e481
页数：3
相关论文
共 50 条
  • [1] Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma
    Chen, Qin
    Wang, Jing
    Wang, Xinyue
    Yin, Yan
    Wang, Xuan
    Song, Zhenchun
    Xing, Bin
    Li, Yajing
    Zhang, Jingjing
    Qin, Jianwen
    Jiang, Richeng
    CLINICAL LUNG CANCER, 2024, 25 (01) : 29 - 38
  • [2] Comments on "Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma"
    Huang, Jie
    CLINICAL LUNG CANCER, 2024, 25 (08) : e446 - e447
  • [3] Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
    Ikeda, Sadakatsu
    Goodman, Aaron M.
    Cohen, Philip R.
    Jensen, Taylor J.
    Ellison, Christopher K.
    Frampton, Garrett
    Miller, Vincent
    Patel, Sandip P.
    Kurzrock, Razelle
    NPJ GENOMIC MEDICINE, 2016, 1
  • [4] Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
    Sadakatsu Ikeda
    Aaron M Goodman
    Philip R Cohen
    Taylor J Jensen
    Christopher K Ellison
    Garrett Frampton
    Vincent Miller
    Sandip P Patel
    Razelle Kurzrock
    npj Genomic Medicine, 1
  • [5] Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.
    Vilbert, Maysa
    Priantti, Jonathan N.
    Madeira, Thiago
    Moraes, Francisco Cezar A.
    Tojjari, Alireza
    Sahin, Ibrahim Halil
    Cavalcante, Ludimila
    Saeed, Anwaar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 366 - 366
  • [6] The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer
    Zhang, Shuling
    Bai, Xueli
    Shan, Fengping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
  • [7] Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma
    Loo, Kimberly
    Daud, Adil
    IMMUNOTHERAPY, 2016, 8 (07) : 775 - 784
  • [8] Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma
    Koh, Young wha
    Han, Jae-ho
    Haam, Seokjin
    Lee, Hyun woo
    ANTICANCER RESEARCH, 2024, 44 (05) : 2081 - 2089
  • [9] Variations in PD1, PD-L1, IDO1 and VEGR2 genes and association with outcomes in advanced head and neck squamous cell carcinoma (HNSCC) patients treated with anti-PD1/PD-L1 based immunotherapy
    Saada-Bouzid, E.
    Refae, S.
    Ebran, N.
    Gal, J.
    Peyrade, F.
    Guigay, J.
    Milano, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] PD-L1 in oral squamous cell carcinoma
    Ragos, Vasileios
    Mastronikolis, Nicholas S.
    Tsiambas, Evangelos
    Fotiades, Panagiotis P.
    JOURNAL OF BUON, 2018, 23 (03): : 835 - 836
12345